Bruno Linetzky

Jul 31, 2024 | heart.bmj.com | Harlan M. Krumholz |Naveed Sattar |Bruno Linetzky |Palash Sharma

DiscussionIn the SURMOUNT-1 trial, in addition to substantial body weight reduction, tirzepatide demonstrated robust and sustained BP lowering in people with overweight or obesity over 72 weeks of treatment. Tirzepatide lowered SBP and DBP over the first 24 weeks, followed by maintenance through 72 weeks. By the end of the study, tirzepatide led to a 6.8 mm Hg lower mean SBP than placebo and a 4.2 mm Hg lower DBP.